Location and size a determinant in physician access: study

Share this article:

Nearly a quarter of all office-based physicians require pharmaceutical or medical device sales reps to make an appointment, according to a SK&A Information Services study.

The study found a direct correlation between the number of physicians in an office and appointment requirements. For example, in offices with 10 doctors or more, 40.02% of the 230,000 medical practices surveyed require an appointment. The medical practices represent 640,000 physicians, according to the study, which surveyed physicians' offices by telephone. Seventeen percent of all physicians surveyed refuse to see sales reps at any time.

In other data, Minnesota, Montana and Washington were the most hostile to sales reps, with 35.56% of the physicians surveyed in Minnesota reporting that they will not see reps at all, followed by 32.91% in Montana, and 32.67% in Washington, according to the study. The states most open to sales reps–Louisiana, Kentucky and Mississippi–won't see reps 16.35%, 16.33% and 15.85% of the time, respectively.

Pediatric Hematology/Oncology physicians are most ardent about appointments, requiring them at a rate of 66.61%. Neuroradiology specialists, pathologists and diagnostic radiologists offered the most limited access for reps; the three groups decline visits at an average rate of 91.24%, according to the study. Allergists/Immunologists, dermatologists and gastroenterologists were the three groups most likely to see sales reps.

Share this article:
You must be a registered member of MMM to post a comment.

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...